IT201900003843A1 - Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG) - Google Patents

Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)

Info

Publication number
IT201900003843A1
IT201900003843A1 IT102019000003843A IT201900003843A IT201900003843A1 IT 201900003843 A1 IT201900003843 A1 IT 201900003843A1 IT 102019000003843 A IT102019000003843 A IT 102019000003843A IT 201900003843 A IT201900003843 A IT 201900003843A IT 201900003843 A1 IT201900003843 A1 IT 201900003843A1
Authority
IT
Italy
Prior art keywords
egcg
fibroids
vitamin
agent
treatment
Prior art date
Application number
IT102019000003843A
Other languages
English (en)
Inventor
Vittorio Unfer
Original Assignee
Lo Li Pharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lo Li Pharma Srl filed Critical Lo Li Pharma Srl
Priority to IT102019000003843A priority Critical patent/IT201900003843A1/it
Priority to CN202080021135.XA priority patent/CN113573706B/zh
Priority to HUE20710518A priority patent/HUE067061T2/hu
Priority to BR112021018308A priority patent/BR112021018308A2/pt
Priority to PL20710518.0T priority patent/PL3937927T3/pl
Priority to ES20710518T priority patent/ES2981336T3/es
Priority to MX2021010491A priority patent/MX2021010491A/es
Priority to GEAP202015739A priority patent/GEP20247615B/en
Priority to CA3130592A priority patent/CA3130592A1/en
Priority to SM20240180T priority patent/SMT202400180T1/it
Priority to PCT/EP2020/056799 priority patent/WO2020187729A1/en
Priority to HRP20240970TT priority patent/HRP20240970T1/hr
Priority to KR1020217033446A priority patent/KR20210139390A/ko
Priority to PE2021001522A priority patent/PE20220130A1/es
Priority to EA202192524A priority patent/EA202192524A1/ru
Priority to UY0001038608A priority patent/UY38608A/es
Priority to UAA202104915A priority patent/UA127910C2/uk
Priority to US17/439,168 priority patent/US20220160734A1/en
Priority to SG11202108937VA priority patent/SG11202108937VA/en
Priority to MA055281A priority patent/MA55281A/fr
Priority to RS20240732A priority patent/RS65682B1/sr
Priority to EP20710518.0A priority patent/EP3937927B1/en
Priority to ARP200100727A priority patent/AR118372A1/es
Publication of IT201900003843A1 publication Critical patent/IT201900003843A1/it
Priority to JOP/2021/0222A priority patent/JOP20210222A1/ar
Priority to CONC2021/0011789A priority patent/CO2021011789A2/es
Priority to CL2021002374A priority patent/CL2021002374A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IT102019000003843A 2019-03-15 2019-03-15 Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG) IT201900003843A1 (it)

Priority Applications (26)

Application Number Priority Date Filing Date Title
IT102019000003843A IT201900003843A1 (it) 2019-03-15 2019-03-15 Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
RS20240732A RS65682B1 (sr) 2019-03-15 2020-03-13 Tretman fibroida vitaminom d i agensom kao što je epigalokatehin galat (egcg)
PE2021001522A PE20220130A1 (es) 2019-03-15 2020-03-13 Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg)
BR112021018308A BR112021018308A2 (pt) 2019-03-15 2020-03-13 Vitamina d e um ou mais agente, composição e uso da vitamina d e um ou mais agente ou da composição
PL20710518.0T PL3937927T3 (pl) 2019-03-15 2020-03-13 Leczenie włókniaków witaminą D i środkiem takim jak galusan epigalokatechiny (EGCG)
ES20710518T ES2981336T3 (es) 2019-03-15 2020-03-13 Tratamiento de fibromas con vitamina D y un agente tal como galato de epigalocatequina (EGCG)
MX2021010491A MX2021010491A (es) 2019-03-15 2020-03-13 Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg).
GEAP202015739A GEP20247615B (en) 2019-03-15 2020-03-13 Treatment of fibroids with vitamin d and an agent such as epigallocatechin gallate (egcg)
CA3130592A CA3130592A1 (en) 2019-03-15 2020-03-13 Treatment of fibroids with vitamin d and an agent such as epigallocatechin gallate (egcg)
SM20240180T SMT202400180T1 (it) 2019-03-15 2020-03-13 Trattamento dei fibromi con vitamina d e un agente come l'epigallocatechina gallato (egcg)
PCT/EP2020/056799 WO2020187729A1 (en) 2019-03-15 2020-03-13 Treatment of fibroids with vitamin d and an agent such as epigallocatechin gallate (egcg)
HRP20240970TT HRP20240970T1 (hr) 2019-03-15 2020-03-13 Liječenje fibroma vitaminom d i sredstvom kao što je epigalokatehin galat (egcg)
KR1020217033446A KR20210139390A (ko) 2019-03-15 2020-03-13 비타민 d 및 에피갈로카테킨 갈레이트(egcg)와 같은 제제를 이용한 섬유종의 치료
CN202080021135.XA CN113573706B (zh) 2019-03-15 2020-03-13 用维生素d和表没食子儿茶素没食子酸酯(egcg)等药物治疗纤维瘤
EA202192524A EA202192524A1 (ru) 2019-03-15 2020-03-13 Лечение фиброида витамином d и агентом, таким как эпигаллокатехин галлат (egcg)
MA055281A MA55281A (fr) 2019-03-15 2020-03-13 Traitement de léiomyomes avec de la vitamine d et un agent tel que le gallate d'épigallocatéchine (egcg)
UAA202104915A UA127910C2 (uk) 2019-03-15 2020-03-13 Лікування фіброїдів вітаміном d та засобом, таким як ґалат епіґалокатехіну (egcg)
US17/439,168 US20220160734A1 (en) 2019-03-15 2020-03-13 Treatment of fibroids with vitamin d and an agent such as epigallocatechin gallate (egcg)
SG11202108937VA SG11202108937VA (en) 2019-03-15 2020-03-13 Treatment of fibroids with vitamin d and an agent such as epigallocatechin gallate (egcg)
UY0001038608A UY38608A (es) 2019-03-15 2020-03-13 Vitamina d y uno o más agentes y composición
HUE20710518A HUE067061T2 (hu) 2019-03-15 2020-03-13 Fibrómák kezelése D-vitaminnal és egy hatóanyaggal, például epigallokatekin-galláttal (EGCG)
EP20710518.0A EP3937927B1 (en) 2019-03-15 2020-03-13 Treatment of fibroids with vitamin d and an agent such as epigallocatechin gallate (egcg)
ARP200100727A AR118372A1 (es) 2019-03-15 2020-03-16 Vitamina d y uno o más agentes y composición
JOP/2021/0222A JOP20210222A1 (ar) 2019-03-15 2021-08-12 علاج الأورام الليفية بواسطة فيتامين د وعامل مثل جالات يبيجالوكاتشين (egcg)
CONC2021/0011789A CO2021011789A2 (es) 2019-03-15 2021-09-08 Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg)
CL2021002374A CL2021002374A1 (es) 2019-03-15 2021-09-10 Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000003843A IT201900003843A1 (it) 2019-03-15 2019-03-15 Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)

Publications (1)

Publication Number Publication Date
IT201900003843A1 true IT201900003843A1 (it) 2020-09-15

Family

ID=66690890

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102019000003843A IT201900003843A1 (it) 2019-03-15 2019-03-15 Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)

Country Status (26)

Country Link
US (1) US20220160734A1 (it)
EP (1) EP3937927B1 (it)
KR (1) KR20210139390A (it)
CN (1) CN113573706B (it)
AR (1) AR118372A1 (it)
BR (1) BR112021018308A2 (it)
CA (1) CA3130592A1 (it)
CL (1) CL2021002374A1 (it)
CO (1) CO2021011789A2 (it)
EA (1) EA202192524A1 (it)
ES (1) ES2981336T3 (it)
GE (1) GEP20247615B (it)
HR (1) HRP20240970T1 (it)
HU (1) HUE067061T2 (it)
IT (1) IT201900003843A1 (it)
JO (1) JOP20210222A1 (it)
MA (1) MA55281A (it)
MX (1) MX2021010491A (it)
PE (1) PE20220130A1 (it)
PL (1) PL3937927T3 (it)
RS (1) RS65682B1 (it)
SG (1) SG11202108937VA (it)
SM (1) SMT202400180T1 (it)
UA (1) UA127910C2 (it)
UY (1) UY38608A (it)
WO (1) WO2020187729A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200011114A1 (it) * 2022-05-26 2023-11-26 Recordati Ind Chimica E Farmaceutica S P A “uso dell’associazione tadalafil e vitamina d3 per la preparazione di un prodotto per il trattamento orale della ipertrofia prostatica benigna e relativi metodi produttivi”

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039967A (en) 1997-04-03 2000-03-21 Point Biomedical Corporation Intravesical drug delivery system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US20050032741A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin Compositions
US7910138B2 (en) * 2003-10-09 2011-03-22 Medigene Ag Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin
US8221803B1 (en) * 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
CN102670584A (zh) * 2011-03-18 2012-09-19 江苏凯吉生物科技有限公司 没食子儿茶素没食子酸酯在制备抗良性前列腺增生药物中的应用
CN105029406A (zh) * 2015-04-14 2015-11-11 劲膳美生物科技股份有限公司 子宫肌瘤医学配方食品
AU2016247674A1 (en) * 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
CN104856996B (zh) * 2015-04-27 2018-01-05 南京舒鹏生物科技有限公司 吡咯喹啉醌、其衍生物和/或盐新的药用用途以及药用组合物
CN105054025B (zh) * 2015-08-09 2017-11-14 青岛大学附属医院 一种用于炎症性肠病患者的低脂低渗低渣型肠内营养粉剂
WO2017132775A1 (en) * 2016-02-05 2017-08-10 Viteava Pharmaceuticals Inc. Novel compositions and methods for the treatment of leiomyoma
WO2023099763A1 (en) * 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039967A (en) 1997-04-03 2000-03-21 Point Biomedical Corporation Intravesical drug delivery system
US6207180B1 (en) 1997-04-03 2001-03-27 Thomas B. Ottoboni Intravesical drug delivery

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Remington ''The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
BERGE S. M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
BIGHLEY ET AL.: "Encyclopedia of Pharmaceutical Technology", vol. 13, 1996, MARCEL DEKKER INC, pages: 453 - 497
CHEETHAM PHILIPPA J: "Role of Complimentary Therapy for Male LUTS", CURRENT UROLOGY REPORTS, CURRENT SCIENCE, US, vol. 14, no. 6, 13 September 2013 (2013-09-13), pages 606 - 613, XP035375508, ISSN: 1527-2737, [retrieved on 20130913], DOI: 10.1007/S11934-013-0372-3 *
GOULD P. L., INT. J. PHARM, vol. 33, 1986, pages 201 - 217
INGBER DFOLKMAN J: "Mechanochemical switching between growth and differentiation during fibroblast growth factor stimulated angiogenesis in vitro: role of extracellular matrix", J CELL BIOL, vol. 109, 1989, pages 317 - 330
LEPPERT PCBAGINSKI TPRUPAS CCATHERINO WHPLETCHER SSEGARS JH: "Comparative ultrastructure of collagen fibrils in uterine leiomyoma and normal myometrium", FERTIL STERIL, vol. 82, 2004, pages 1182 - 1187, XP004596324, DOI: doi:10.1016/j.fertnstert.2004.04.030
MALIK MSEGARS JCATHERINO WH: "Integrin (31 regulates leiomyoma cytoskeletal integrity and growth", MATRIX BIOL, vol. 7-8, 2012, pages 389 - 397
MICHAL CIEBIERA ET AL: "Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 18, no. 12, 1 December 2017 (2017-12-01), pages 2586, XP055641506, DOI: 10.3390/ijms18122586 *
TOMASEK JJGABBIANI GHINZ BCHAPPONIER CBROWN RA: "Myofibroblasts and mechano-regulation of connective tissue remodeling", NAT REV MOL CELL BIOL, vol. 3, 2002, pages 349 - 363
ZHANG, D.AL-HENDY, M.RICHARD-DAVIS, G.MONTGOMERY-RICE, V.SHARAN, C.RAJARATNAM, V.KHURANA, A.AL-HENDY, A.: "Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice", AM. J. OBSTET. GYNECOL., vol. 202, 2010, XP026942895, DOI: doi:10.1016/j.ajog.2009.10.885

Also Published As

Publication number Publication date
EP3937927A1 (en) 2022-01-19
HUE067061T2 (hu) 2024-09-28
KR20210139390A (ko) 2021-11-22
UY38608A (es) 2020-10-30
CA3130592A1 (en) 2020-09-24
CN113573706A (zh) 2021-10-29
US20220160734A1 (en) 2022-05-26
JOP20210222A1 (ar) 2021-08-12
SG11202108937VA (en) 2021-09-29
PL3937927T3 (pl) 2024-09-02
GEP20247615B (en) 2024-03-25
PE20220130A1 (es) 2022-01-27
ES2981336T3 (es) 2024-10-08
CO2021011789A2 (es) 2021-09-20
MA55281A (fr) 2022-01-19
CN113573706B (zh) 2025-02-07
SMT202400180T1 (it) 2024-07-09
UA127910C2 (uk) 2024-02-07
EA202192524A1 (ru) 2021-11-19
WO2020187729A1 (en) 2020-09-24
BR112021018308A2 (pt) 2021-11-23
AR118372A1 (es) 2021-09-29
EP3937927B1 (en) 2024-04-17
EP3937927C0 (en) 2024-04-17
HRP20240970T1 (hr) 2024-10-25
MX2021010491A (es) 2021-10-01
RS65682B1 (sr) 2024-07-31
CL2021002374A1 (es) 2022-04-18

Similar Documents

Publication Publication Date Title
EP4516355A3 (en) Stable cannabinoid formulations
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
PH12017502375A1 (en) Method of treating inflammation using natural compounds and/or diet
NI202000085A (es) Moduladores de la expresión de apol1
EP3711765A4 (en) COMPOSITION OF CANNABIDIOL / CANNABIS EXTRACT AND CAFFEINE AND USE OF THE COMPOSITION
EP4028059A4 (en) STABLE MEDICAL CANNABIDIOL COMPOSITIONS
EP3817750A4 (en) CANNABIDIOL COMBINATION COMPOSITIONS
EP3723739A4 (en) PARASITICIDAL ISOXAZOLINE FORMULATIONS AND METHODS OF TREATMENT OF BLEPHARITIS
EP4161900A4 (en) Cannabidiolic acid (cbda) derivatives and uses thereof
EP3582768A4 (en) CANNABINOID FORMULATIONS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASES
EP3946316A4 (en) PHARMACEUTICAL CANNABIDIOL COMPOSITIONS
EP4106870A4 (en) Compositions and therapeutic uses of cannabidiol
EP3908352A4 (en) INHALABLE DOSAGE FORM OF CANNABINOID EXTRACT
BR112018067918A2 (pt) formulações livres de solvente de substâncias ativas com baixo ponto de fusão
IT201900003843A1 (it) Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
EP3804728C0 (en) COMPOSITION COMPRISING AS ACTIVE INGREDIENT AN INOTODIOL COMPOUND INTENDED FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES
MA50163A (fr) Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité
PH12018501646A1 (en) Compositions and methods for treating infections
CL2012001485A1 (es) Compuestos derivados de benzofurano, benzooxazol y benzo[d]oxadol, como inhibidores de mek; composicion farmaceutica que los comprende, utiles en el tratamiento de enfermedades hiperproliferativas, tales como cancer e inflamacion.
EP4081206A4 (en) PRODUCTION OF CANNABICHROMES AND RELATED CANNABINOIDS
DOP2013000289A (es) Una composición antiparasitaria y método de tratamiento
EP3456335A4 (en) PITHECELLOBIUM CLYPEARIA BENTH, EXTRACT AND APPLICATION FOR THE PREPARATION OF AN ANTIMICROBIAL AGENT
EP3654966A4 (en) AMORPIOUS DISPERSIONS OF EPIGALLOCATECHINGALLATE
KR102459998B9 (ko) 신규한 1-테트라론 찰콘계 화합물 및 이를 유효성분으로 함유하는 염증 질환 예방 또는 치료용 조성물